# US 2023/0054895 A1 · Methods for inducing biostasis in a cell, tissue or organ

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0054895 A1
- Document ID: US20230054895A1
- Status: Published application
- Kind: A1
- Application number: 17/791,775
- Filed: 2021-01-08
- Published: 2023-02-23
- Earliest claimed: 2020-01-10
- Assignees: President and Fellows of Harvard College; Trustees of Tufts College
- Applicants: President and Fellows of Harvard College; Trustees of Tufts College
- Inventors: Takako TAKEDA; Megan Sperry; Erica Gardner; Michael Levin; Charles Reilly; Richard Novak; Donald E. Ingber
- Web page: https://patentgrep.com/patent/US20230054895A1

## CPC

- A01N 1/126: Physiologically active agents, e.g. antioxidants or nutrients
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are methods for promoting biostasis or preservation of a cell, tissue or organ during cancer treatment or for transplantation comprising contacting the cell, tissue or organ with an agonist of the δ-opioid receptor, SNC-80, an or Donepezil. Further provided herein is a method of treating a hematological neoplastic disease.

## Claims

### Claim 1

A method of inducing biostasis in a tissue or organ, the method comprising contacting the tissue or organ in need of preservation with an agent that alters the function of at least one ion channel selected from the group consisting of EAAT1 ion channel and NCX1 ion channel, wherein the contacted tissue or organ exhibits biostasis.

### Claim 2

A method of tissue or organ transplant, the method comprising contacting a donor tissue or organ in situ or ex vivo with an agent that alters the function of at least one ion channel selected from the group consisting of EAAT1 ion channel and NCX1 ion channel.

### Claim 3 (depends on 1)

The method of claim 1, wherein the agent further activates the δ-opioid receptor following contact.

### Claim 4 (depends on 1)

The method of claim 1, wherein the agent does not activate the δ-opioid receptor following contact.

### Claim 5

(canceled)

### Claim 6

(canceled)

### Claim 7 (depends on 1)

The method of claim 1, wherein altering the function is inhibiting, slowing, or activating the function.

### Claim 8 (depends on 1)

The method of claim 1, wherein the tissue is selected from the group consisting of cornea, bone, tendon, pancreas islet, heart valve, nerve, vascular, deep tissue flap, fat tissue, muscle, and vein.

### Claim 9 (depends on 1)

The method of claim 1, wherein the organ is selected from the group consisting of intestine, stomach, heart, kidney, bladder, pancreas, liver, lung, brain, skin, uterus, digit, and limb.

### Claim 10 (depends on 1)

The method of claim 1, wherein the contacting suppresses the metabolism or induces biostasis of the tissue or organ.

### Claim 11 (depends on 1)

The method of claim 1, wherein the agent is SNC-80 or donepezil, or
a derivative, analog, or variant of SNC-80 or donepezil that alters the function of at least one ion channel selected from the group consisting of EAAT1 ion channel and NCX1 ion channel.

### Claim at position 12

-15. (canceled)

### Claim 16 (depends on 1)

The method of claim 1, further comprising contacting with at least a second agent that alters the function of at least one ion channel selected from the group consisting of EAAT1 ion channel and NCX1 ion channel.

### Claim 17 (depends on 16)

The method of claim 16, wherein the agonist or agent and the at least second agent are contacted at substantially the same time or at different times.

### Claim 18 (depends on 16)

The method of claim 16, wherein the at least second agent is an inhibitor of the NCX1 ion channel.

### Claim 19 (depends on 18)

The method of claim 18, wherein the inhibitor is KB-R7943 mesylate.

### Claim 20 (depends on 1)

The method of claim 1, wherein the agent or agonist is comprised in a vehicle that is deuterium oxide.

### Claim 21 (depends on 1)

The method of claim 1, wherein the contacting is a single contact, or reoccurring contacting.

### Claim 22 (depends on 1)

The method of claim 1, wherein the contacting is performed for at least 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 10 hours, 18 hours, 24 hours, 36 hours 48, hour, 96 hours or more.

### Claim 23 (depends on 1)

The method of claim 1, further comprising contacting the tissue or organ with at least a second, biostatic compound.

### Claim 24 (depends on 1)

The method of claim 1, wherein the at least a second compound is selected from the group consisting of hydrogen sulfide, nitrogen, argon, Oligomycin A, rotenone, 2-deoxyglucose, adenosine monophosphate (AMP), a neuropeptide, deferoxamine, and a prolyl hydroxylase inhibitor.

### Claim at position 22

-30. (canceled)

### Claim 31

A composition comprising at least two agents that alter the function of at least one ion channel selected from the group consisting of EAAT1 ion channel and NCX1 ion channel.

### Claim 32

(canceled)

### Claim 33 (depends on 31)

The composition of claim 31, further comprising deuterium oxide.

### Claim 34

(canceled)

### Claim 35

(canceled)
